Clinical Research Directory
Browse clinical research sites, groups, and studies.
Alzheimer's Disease Research Center (ADRC) PET Component Study
Sponsor: Patrick Lao
Summary
The purpose of this study is to further engage and characterize Alzheimer's Disease Research Center (ADRC) participants through additional research opportunities, particularly PET imaging. Amyloid and Tau PET imaging will be collected in 24 participants per year, for a total of 120 participants over five years. All participants will be followed longitudinally, including through potential transitions from normal aging to mild cognitive impairment (MCI) and Alzheimer's disease and related dementias (ADRD).
Official title: Alzheimer's Disease Research Center PET Component
Key Details
Gender
All
Age Range
50 Years - Any
Study Type
INTERVENTIONAL
Enrollment
120
Start Date
2026-08-06
Completion Date
2033-05-31
Last Updated
2026-08-11
Healthy Volunteers
Yes
Interventions
18F-MK6240
MK-6240 is experimental but has been used in several human studies before and has been proven to accurately measure tau in the brain.
18F-Florbetaben (FBB)
Florbetaben has been approved by the FDA to help diagnose Alzheimer's disease. Florbetaben measures amyloid in the brain.
Locations (1)
Columbia University Irving Medical Center
New York, New York, United States